-- 据周五提交上海证券交易所的披露信息显示，台湾食品药物管理署已批准中华医药科技股份有限公司（SHA:688108）的颅内血栓抽吸导管上市。 该导管名为APACHI，用于恢复急性缺血性中风患者的血流。
Related Articles
Equities
Lu'an Environmental Energy 2025 Profit Down 54%; Shares Up 3%
Shanxi Lu'an Environmental Energy Development (SHA:601699) posted 2025 attributable net profit of 1.12 billion yuan, down 54% from 2.45 billion yuan the previous year.Earnings per share declined to 0.37 yuan from 0.82 yuan, according to a weekend filing with the Shanghai bourse.Operating revenue fell 22% year over year to 27.8 billion yuan from 35.9 billion yuan.Shares of the coal miner rose 3% in recent trade.
$SHA:601699
Asia
WA1 Resources Reports AU$131 million Cash Balance at End of Q1, Shares Up 7%
WA1 Resources (ASX:WA1) reported a cash balance of about AU$131 million as at March 31, according to a Monday Australian bourse filing.The company said it has now received all data inputs for a mineral resource estimate update expected in the June quarter.The company completed essential data capture activities in 2025, which is now facilitating project development studies, permitting and approvals workstreams, the filing added.The company's shares rose 7% in recent Monday trade.
$ASX:WA1
Asia
Bank of Ningbo Q1 Profit, Operating Income Up 10%
Bank of Ningbo (SHE:002142) posted first-quarter attributable net profit of 8.18 billion yuan, up 10% from 7.42 million yuan the previous year.Earnings per share rose to 1.24 yuan from 1.12 yuan, according to a weekend filing with the Shenzhen bourse.Operating income rose 10% year over year to 20.4 billion yuan from 18.5 billion yuan.Shares of the bank rose 3% in recent trade.
$SHE:002142